All articles tagged with #revolution medicines
The FDA has approved daraxonrasib (Rasonque), the first drug in its class to target RAS mutations, a breakthrough for pancreatic cancer. In a trial of 500 patients, the drug doubled median survival to 13.2 months compared to 6.7 months for chemotherapy. Developed by Revolution Medicines, the drug addresses a target previously deemed untargetable, offering new hope for a disease with a 13% five-year survival rate.
The FDA approval of daraxonrasib (Rasonque) for pancreatic cancer has created a critical access gap. While the drug nearly doubles median survival, commercial insurance coverage lags behind regulatory approval, leaving patients in a dangerous interim period. Expanded access programs close upon approval, but payers often take weeks or months to update formularies, forcing some patients to pay high out-of-pocket costs or face treatment interruptions.
Revolution Medicines' Rasonque, a daily oral pill for metastatic pancreatic cancer, received rapid FDA approval and a high list price of $39,800 per month. Analysts project it could become a multi-billion-dollar blockbuster, while patient advocacy groups highlight its unprecedented survival benefits and the critical need for financial assistance programs.
The FDA has approved daraxonrasib, marketed as Rasonque, a daily oral pill for metastatic pancreatic cancer. In phase 3 trials, the drug nearly doubled median survival to 13.2 months compared to 6.7 months for chemotherapy. While the list price is approximately $477,000 annually, actual out-of-pocket costs vary significantly based on insurance coverage and assistance programs.
The FDA has approved daraxonrasib, branded as Rasonque, for metastatic pancreatic cancer, marking a historic first for RAS-targeted therapy. While clinical data shows a doubling of survival, concerns remain regarding the drug's high cost, transition from expanded access, and unclear criteria for first-line use.
The FDA has approved Rasonque, a daily pill that nearly doubles survival for advanced pancreatic cancer. Priced at $39,800, it targets a long-unreachable mutation, signaling a major shift in oncology.
The FDA has approved daraxonrasib (Rasonque), a daily oral pill developed by Revolution Medicines, for metastatic pancreatic cancer. In a Phase 3 trial of 500 patients, the drug nearly doubled median survival to 13.2 months compared to 6.7 months for chemotherapy. This is the first targeted therapy for this disease, offering a non-chemotherapy option for patients with specific KRAS mutations.
The U.S. Food and Drug Administration has approved daraxonrasib, a daily oral pill for metastatic pancreatic cancer, after an expedited review process. The drug, marketed as Rasonque, blocks the RAS protein that drives tumor growth and was shown to double median survival in clinical trials. It is now available in the U.S. at a price of $39,800 for a 30-day supply, with potential co-pay assistance for insured patients.
Revolution Medicines revealed early data for a two-KRAS inhibitor drug combination, including Daraxonrasib, and plans a Phase 3 trial, signaling potential progress in targeting KRAS-driven cancers.
A two-drug combo of Tango Therapeutics’ vopimetostat and Revolution Medicines’ daraxonrasib produced durable responses in the large majority of pancreatic cancer patients in an early-stage trial, prompting Tango to advance the approach to a Phase 3 study.
Patients with pancreatic cancer are pursuing Revolution Medicines' experimental drug daraxonrasib through expanded-access programs as the company nears potential approval. While there is optimism the treatment could extend lives, demand is surging and production may not keep up, raising concerns about who receives the drug first and how access will be allocated.
A new oral drug, daraxonrasib, targets the KRAS-driven mechanism in pancreatic cancer by engaging cyclophilin A to shut down KRAS signaling. In a Phase 3 trial of 500 patients with metastatic pancreatic cancer who had prior treatment, daraxonrasib nearly doubled median survival from 6.7 to 13.2 months and reduced the risk of death by about 60% versus standard chemotherapy. The most common side effects were a skin rash, stomatitis, diarrhea, nausea and vomiting, though discontinuation due to adverse effects was lower and quality of life improved. Regulatory review by the FDA and other global authorities is the immediate next step, with expedited review likely; if approved, the drug could reach clinics within months and herald a shift toward targeted, personalized therapy and potential combination approaches to prevent resistance.
ASCO data show Revolution Medicines’ oral daraxonrasib, a molecular glue that blocks RAS, delaying cancer symptoms by more than nine months and extending median survival to 13.2 months in advanced pancreatic cancer; while not curative, it improves length and quality of life versus chemotherapy, with side effects like rash and mouth sores that are usually manageable.
Revolution Medicines has begun shipping its experimental pancreatic cancer drug, daraxonrasib, under an FDA-authorized early-access program after Phase 3 results showed patients lived nearly twice as long as those on standard chemotherapy, fueling high demand ahead of formal FDA approval.
A pancreatic cancer patient on Revolution Medicines' KRAS inhibitor daraxonrasib reports a dramatic extension of life, illustrating how targeting historically 'undruggable' KRAS can yield durable benefits and fueling optimism for KRAS inhibitors across pancreatic and other KRAS-mutant cancers.